{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T19:15:09Z","timestamp":1757704509866,"version":"3.41.2"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Chimeric antigen receptor T (CAR-T) cell therapy is more effective in relapsed or refractory diffuse large B cell lymphoma (DLBCL) than other therapies, but a high proportion of patients relapse after CAR-T cell therapy owing to antigen escape, limited persistence of CAR-T cells, and immunosuppression in the tumor microenvironment. CAR-T cell exhaustion is a major cause of relapse. Epigenetic modifications can regulate T cell activation, maturation and depletion; they can be applied to reduce T cell depletion, improve infiltration, and promote memory phenotype formation to reduce relapse after CAR-T cell therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Purpose<\/jats:title><jats:p>We propose to develop and validate <jats:italic>in vitro<\/jats:italic> the function of novel CAR-T cells for the treatment of DLBCL, which simultaneously express an anti-CD19 CAR with lysine-specific demethylase 1 (LSD1) short hairpin (sh)RNA to prevent depletion and prolong the survival of CAR-T cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We designed an shRNA sequence targeting LSD1 mRNA, and created a vector with the following elements: the U6 promoter driving expression of the LSD1 shRNA sequence, the EF1a promoter driving a second-generation anti-CD19 CAR sequence encoding an anti-CD19 single-chain variable fragment (FMC63), the CD8 hinge and transmembrane structural domains, the CD28 co-stimulatory structural domain, and the CD3\u03b6-activating structural domain. The MFG-LSD1 shRNA anti-CD19 CAR plasmid was first constructed, then packaged in retroviral vectors and transduced into human primary peripheral blood mononuclear cell-derived T cells to generate the corresponding CAR-T cells. We examined by flow cytometry the efficiency of two CAR-T cells in killing U-2932 cells (a human DLBCL line) upon co-culture with RNAU6 anti-CD19 CAR-T cells or LSD1 shRNA anti-CD19 CAR-T cells. We analyzed Ki-67 staining of the CAR-T cells by flow cytometry on days 0, 5, and 10, and counted the cells to assess expansion. We also used flow cytometry to detect the central memory T cell (TCM) proportion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We detected the expression of the CAR in the CAR-T cells by flow cytometry, and observed transduction rates of 31.5% for RNAU6 anti-CD19 CAR-T cells and 60.7% for LSD1 shRNA anti-CD19 CAR-T cells. The killing efficiency of LSD1 shRNA anti-CD19 CAR-T cells was significantly higher than that of RNAU6 anti-CD19 CAR-T cells at the low effector target ratio. We further found that LSD1 shRNA anti-CD19 CAR-T cells secreted more IFN-\u03b3 and granzyme B than RNAU6 anti-CD19 CAR-T cells. CAR-T cells proliferated after U-2932 cell stimulation and were able to sustain proliferation. After stimulation via U-2932 cell co-culture, both RNAU6 anti-CD19 CAR-T and LSD1 shRNA anti-CD19 CAR-T populations had increased proportions of cells with the TCM phenotype, with a higher percentage among LSD1 shRNA anti-CD19 CAR-T cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We developed a novel, feasible CD19-LSD1 shRNA CAR-T cell strategy for the treatment of DLBCL. Our <jats:italic>in vitro<\/jats:italic> assay results showed that LSD1 shRNA anti-CD19 CAR-T cells more effectively killed target cells than RNAU6 anti-CD19 CAR-T cells, and developed a higher proportion of TCM phenotype cells. LSD1 shRNA anti-CD19 CAR-T cells may represent a potential treatment for DLBCL.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1521778","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T06:14:25Z","timestamp":1736748865000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["In vitro functional validation of anti-CD19 chimeric antigen receptor T cells expressing lysine-specific demethylase 1 short hairpin RNA for the treatment of diffuse large B cell lymphoma"],"prefix":"10.3389","volume":"15","author":[{"given":"Zhi","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingxin","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiqing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-01-785840","article-title":"Chimeric antigen receptor-modified T cells: CD19 and the road beyond","volume":"131","author":"Salter","year":"2018","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0421-7","article-title":"A safe and potent anti-CD19 CAR T cell therapy","volume":"25","author":"Ying","year":"2019","journal-title":"Nat Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"100826","DOI":"10.1016\/j.currproblcancer.2021.100826","article-title":"CAR T-cell therapy for B-cell lymphoma","volume":"46","author":"Denlinger","year":"2022","journal-title":"Curr Probl Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/hon.31531","article-title":"CAR T-cell therapy in large B cell lymphoma","author":"Boardman","year":"2023","journal-title":"Hematol Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01739-2","article-title":"Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma","volume":"37","author":"Alarcon Tomas","year":"2023","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"112174","DOI":"10.1016\/j.intimp.2024.112174","article-title":"Rapid response in relapsed follicular lymphoma to novel anti-CD19 CAR-T therapy with pseudo-progression and cytomegalovirus infection: A case report","volume":"134","author":"Zhong","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B7","article-title":"Second-line treatment with CAR T-cell therapy for large B-cell lymphoma","volume":"21","author":"Lutfi","year":"2023","journal-title":"Clin Adv Hematol Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1188\/22.CJON.597-601","article-title":"CAR T-cell therapy for relapsed\/refractory aggressive large B-cell lymphoma","volume":"26","author":"Gideon","year":"2022","journal-title":"Clin J Oncol Nurs"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00307-1","article-title":"CD19-directed CAR T cells as first salvage therapy for large B-cell lymphoma: towards a rational approach","volume":"10","author":"Dreger","year":"2023","journal-title":"Lancet Haematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0737-3","article-title":"Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma","volume":"26","author":"Brudno","year":"2020","journal-title":"Nat Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020197","article-title":"Real-world experience of CAR T-cell therapy in older patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"142","author":"Chihara","year":"2023","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.927153","article-title":"CAR-T cell therapy in hematological Malignancies: current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01224-z","article-title":"Epigenetic regulation of T cell exhaustion","volume":"23","author":"Belk","year":"2022","journal-title":"Nat Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00919","article-title":"Tranylcypromine based lysine-specific demethylase 1 inhibitor: summary and perspective","volume":"63","author":"Dai","year":"2020","journal-title":"J Med Chem"},{"key":"B18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13045-019-0811-9","article-title":"LSD1\/KDM1A inhibitors in clinical trials: advances and prospects","volume":"12","author":"Fang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1038\/s41467-024-48607-4","article-title":"Priming with LSD1 inhibitors promotes the persistence and antitumor effect of adoptively transferred T cells","volume":"15","author":"Qiu","year":"2024","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0017","article-title":"Simultaneous inhibition of LSD1 and TGF\u03b2 Enables eradication of poorly immunogenic tumors with anti-PD-1 treatment","volume":"11","author":"Sheng","year":"2021","journal-title":"Cancer Discovery"},{"key":"B21","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cell.2018.05.052","article-title":"LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade","volume":"174","author":"Sheng","year":"2018","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","first-page":"121016","DOI":"10.1016\/j.lfs.2022.121016","article-title":"Recent advances in the production, reprogramming, and application of CAR-T cells for treating hematological Malignancies","volume":"309","author":"Vandghanooni","year":"2022","journal-title":"Life Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2020.02.003","article-title":"Optimized assessment of qPCR-based vector copy numbers as a safety parameter for GMP-grade CAR T cells and monitoring of frequency in patients","volume":"17","author":"Kunz","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.3390\/cancers12102820","article-title":"Assessment of CAR T cell frequencies in axicabtagene ciloleucel and tisagenlecleucel patients using duplex quantitative PCR","volume":"12","author":"Schubert","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/imcb.12254","article-title":"Chimeric antigen receptor T cell persistence and memory cell formation","volume":"97","author":"McLellan","year":"2019","journal-title":"Immunol Cell Biol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/bs.mcb.2021.07.001","article-title":"Generation of CAR-T cells using lentiviral vectors","volume":"167","author":"Poorebrahim","year":"2022","journal-title":"Methods Cell Biol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/bs.mcb.2021.06.014","article-title":"Generation of CAR T-cells using \u03b3-retroviral vector","volume":"167","author":"Watanabe","year":"2022","journal-title":"Methods Cell Biol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-0146-4_8","article-title":"Generation of chimeric antigen receptor T cells using gammaretroviral vectors","volume":"2086","author":"Mo","year":"2020","journal-title":"Methods Mol Biol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"6223","DOI":"10.3390\/ijms20246223","article-title":"Optimizing manufacturing protocols of chimeric antigen receptor T cells for improved anticancer immunotherapy","volume":"20","author":"Stock","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/lipd.12321","article-title":"Fatty acid and oxylipin concentration differ markedly between different fetal bovine serums: A cautionary note","volume":"56","author":"Koch","year":"2021","journal-title":"Lipids"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.876339","article-title":"Impact of manufacturing procedures on CAR T cell functionality","volume":"13","author":"Watanabe","year":"2022","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41423-020-00555-x","article-title":"Clinical development of CAR T cell therapy in China: 2020 update","volume":"18","author":"Wei","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.016","article-title":"The principles of engineering immune cells to treat cancer","volume":"168","author":"Lim","year":"2017","journal-title":"Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00702","article-title":"Prolonged persistence of chimeric antigen receptor (CAR) T cell in adoptive cancer immunotherapy: challenges and ways forward","volume":"11","author":"Jafarzadeh","year":"2020","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006193","article-title":"Long-term safety for patients with tisagenlecleucel-treated relapsed\/refractory diffuse large B-cell lymphoma","volume":"6","author":"Jaeger","year":"2022","journal-title":"Blood Adv"},{"key":"B36","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-020-00910-5","article-title":"Recent advances in CAR-T cell engineering","volume":"13","author":"Huang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"102931","DOI":"10.1016\/j.ebiom.2020.102931","article-title":"CAR-T design: Elements and their synergistic function","volume":"58","author":"Jayaraman","year":"2020","journal-title":"EBioMedicine"},{"key":"B39","doi-asserted-by":"publisher","first-page":"114564","DOI":"10.1016\/j.ejmech.2022.114564","article-title":"A comprehensive comparative study on LSD1 in different cancers and tumor specific LSD1 inhibitors","volume":"240","author":"Dong","year":"2022","journal-title":"Eur J Med Chem"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01915","article-title":"To remember or to forget: the role of good and bad memories in adoptive T cell therapy for tumors","volume":"11","author":"Mondino","year":"2020","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"7366","DOI":"10.1038\/s41467-024-51500-9","article-title":"LSD1 inhibition improves efficacy of adoptive T cell therapy by enhancing CD8(+) T cell responsiveness","volume":"15","author":"Pallavicini","year":"2024","journal-title":"Nat Commun"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1521778\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T06:14:27Z","timestamp":1736748867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1521778\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2024.1521778"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1521778","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2025,1,13]]},"article-number":"1521778"}}